Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768203 | 0.88 | GHSR (0.43) | GHSRCA12CA1CA2CA9 | |
| SCHEMBL6492295 | 0.86 | GHSR (0.45) | GHSRLMNAMAPK1NPSR1CA12 | |
| SCHEMBL6484551 | 0.86 | USP10 (0.48) | LMNA | |
| SCHEMBL6497769 | 0.85 | CA1 (0.48) | GHSRPTGS2MAPK1CA12CA1 | |
| SCHEMBL6770045 | 0.85 | SMN1; SMN2 (0.47) | GHSRPTGS2CA12CA1CA2 | |
| SCHEMBL6493222 | 0.83 | MAPT (0.48) | LMNAMAPK1CA12CA1CA2 | |
| SCHEMBL6481651 | 0.81 | EGFR (0.43) | — | |
| SCHEMBL6481101 | 0.81 | MEN1 (0.45) | LMNAMAPK1CA1CA2 | |
| SCHEMBL6496615 | 0.80 | MAOB (0.49) | CA12CA9 | |
| SCHEMBL6768807 | 0.80 | ALDH1A1 (0.44) | LMNACA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | claimed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | claimed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | claimed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | claimed |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | disclosed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | disclosed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | HDAC8, ZC3HAV1, ZCCHC8 | GHSR 1398/4885PTGS2 2035/4885PTGS1 3306/4885 |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | HDAC8, CDK8, ZC3HAV1 | GHSR 1845/4885PTGS2 3576/4885PTGS1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.